Cambrex is the leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug lifecycle.
Cambrex is the leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug lifecycle. With 13 locations across North America and Europe, the company employs over 2000 experts providing customers with an end-to-end partnership for the research, development, and manufacture of small molecule therapeutics. With over 35 years of experience, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Its drug substance services include API development, scale-up, technology transfer, and manufacturing, as well as specialist technologies and capabilities such as biocatalysis, continuous flow, controlled substances, solid state science, and handling highly potent APIs.
The company also offers expertise in drug product formulation and development of conventional and specialist dosage forms including oral solids, semi-solids, and liquids; as well as fixed dose combinations, paediatric, bi-layer tablets, stick packs, topical, and sterile and non-sterile ointments.
Cambrex provides small volume manufacturing solutions for early clinical phase support, in addition to offering standalone analytical services. These include method development and validation, compendial and release testing, stability storage and testing, material characterisation, impurity isolation and identification, fate and purge studies, microbiology, cleanroom services, and many more.